^
Association details:
| Biomarker: | BRAF wild-type + HER-2 positive |
|---|---|
| Cancer: | Colorectal Cancer |
| Drug: | Herceptin (trastuzumab) (HER2 inhibitor) + Irene (pyrotinib) (EGFR inhibitor, HER2 inhibitor, HER4 inhibitor) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
Dual targeted therapy with pyrotinib and trastuzumab for HER2-positive advanced colorectal cancer: a phase 2 trial
Published date:
11/16/2022
Excerpt:
...patients with HER2-positive recurrent / metastatic CRC were enrolled and received oral pyrotinib 400 mg once a day plus intravenous trastuzumab...All patients were BRAF wild-type. Four patients achieved partial response, with an ORR of 22.2% (4/18; 95% CI, 6.4 to 47.6) and DCR of 61.1% (11/18; 95% CI, 35.8 to 82.7). While the ORR and DCR were 33.3% (4/12; 95% CI, 13.8 to 60.9) and 83.3% (10/12; 95% CI, 51.6 to 97.9), respectively, in RAS wild-type patients....Pyrotinib combined with trastuzumab showed promising antitumor activity and a manageable safety profile in patients with RAS/BRAF wild-type HER2-positive advanced CRC.
DOI:
10.1111/cas.15660
Trial ID:
